OXXON THERAPEUTICS LTD has a total of 34 patent applications. Its first patent ever was published in 1998. It filed its patents most often in EPO (European Patent Office), United States and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are JAPAN AS REPRESENTED BY THE DIRECTOR GENERAL OF NAT INSTITUTE OF INFECTIOUS DISEASES, VYCELLIX INC and LIGOCYTE PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 9 | |
#2 | United States | 9 | |
#3 | Australia | 5 | |
#4 | WIPO (World Intellectual Property Organization) | 4 | |
#5 | United Kingdom | 3 | |
#6 | Japan | 2 | |
#7 | Canada | 1 | |
#8 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Schneider Joerg | 21 |
#2 | Plebanski Magdalena | 15 |
#3 | Blanchard Tom | 14 |
#4 | Hanke Tomas | 14 |
#5 | Hill Adrian Vivian Sinton | 9 |
#6 | Mcmichael Andrew James | 8 |
#7 | Smith Geoffrey L | 7 |
#8 | Gilbert Sarah Catherine | 7 |
#9 | Hill Adrian V S | 7 |
#10 | Gilbert Sarah C | 7 |
Publication | Filing date | Title |
---|---|---|
WO2006125983A1 | Compositions for inducing an immune response against hepatitis b | |
WO2006120474A2 | Compositions for inducing an immune response against tumor antigens | |
GB0515658D0 | Compositions for inducing an immune response | |
GB0515439D0 | Composition for inducing an immune response against hepatitis B | |
GB0427001D0 | HSV vaccination vectors | |
US2005175627A1 | HIV pharmaccines | |
AU2004276559A1 | HIV pharmaccines | |
AU2004203141A1 | Methods and reagents for vaccination which generate CD8 T cell immune response | |
AU2002301315B2 | A soluble vaccinia virus protein that binds chemokines | |
AU9332501A | Methods and reagents for vaccination which generate a CD8 T cell immune response |